Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.

Future oncology (London, England) - 1 Aug 2013

Scartozzi Mario, Giampieri Riccardo, Loretelli Cristian, Mandolesi Alessandra, del Prete Michela, Biagetti Simona, Alfonsi Simona, Faloppi Luca, Bianconi Maristella, Bittoni Alessandro, Bearzi Italo, Cascinu Stefano

Abstract excerpt

AIMS: Altered α6β4 integrin expression has been demonstrated in HER-3-negative tumors and may be responsible for anti-HER treatment resistance. The current study aimed to evaluate the interaction between polymorphisms of α6 and β4 integrins and clinical outcome in HER-3-negative, K-RAS wild-type colorectal cancer patients receiving cetuximab. PATIENTS & METHODS: K-RAS analysis was performed via direct sequencing,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Disease-Free Survival

Share to Integrin alpha6

Share to Integrin beta4

Share to Oncogene Protein p21(ras)

Share to Receptor, ErbB-3

Source

Identifiers

PMID: 23617461
DOI: 10.2217/fon.13.72

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.PMID 23617461Read ↗

Single nucleotide polymorphisms of integrin alpha-2 and beta-3 genes are not associated with relapse-free and overall survival in colorectal cancer patients.Semantic proximity Read ↗

Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.Semantic proximity Read ↗

Integrin beta3 Leu33Pro homozygosity and risk of cancer.Semantic proximity Read ↗

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients.Semantic proximity Read ↗

Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk.Semantic proximity Read ↗

The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk.Semantic proximity Read ↗

HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer.Semantic proximity Read ↗

Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.Semantic proximity Read ↗

The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.Semantic proximity Read ↗

Single-nucleotide polymorphisms of integrins are associated with the risk and lymph node metastasis of oral squamous cell carcinoma.Semantic proximity Read ↗

EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.